Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy

Brain

Volumn 127, Issue 9, 2004, Pages 2109-2123

  Halstead, Susan K ^a,d   O'Hanlon, Graham M ^a   Humphreys, Peter D ^a   Morrison, Deborah B ^a   Morgan, Bryan P ^c   Todd, Andrew J ^d   Plomp, Jaap J ^b   Willison, Hugh J ^a,d  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Ganglioside; Membrane attack complex; Miller Fisher syndrome; Neuromuscular junction; Perisynaptic Schwann cell

Indexed keywords

ALPHA LATROTOXIN; ANTIBODY; CD59 ANTIGEN; COMPLEMENT MEMBRANE ATTACK COMPLEX; DIMER; DISIALOSIDE ANTIBODY; EPITOPE; ETHIDIUM; GANGLIOSIDE; GANGLIOSIDE GQ 1B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CELL SURVIVAL; CELL ULTRASTRUCTURE; CONTROLLED STUDY; IMMUNOELECTRON MICROSCOPY; MALE; MICROELECTRODE; MOUSE; NERVE ENDING; NERVE INJURY; NEUROFILAMENT; NEUROMUSCULAR SYNAPSE; NEUROPATHY; NEUROTRANSMITTER RELEASE; NONHUMAN; PARALYSIS; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; SCHWANN CELL;

ANIMALS; ANTIBODIES; ANTIGENS, CD59; CELL DEATH; CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; ETHIDIUM; GANGLIOSIDES; HUMANS; IMMUNIZATION, PASSIVE; INTERCALATING AGENTS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MICROSCOPY, IMMUNOELECTRON; MOTOR NEURONS; NERVE GROWTH FACTORS; NERVOUS SYSTEM AUTOIMMUNE DISEASE, EXPERIMENTAL; NEUROMUSCULAR JUNCTION; SCHWANN CELLS;

EID: 4344576359     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh231     Document Type: Article

References (54)

1. Acosta JA, Benzaquen LR, Goldstein DJ, Tosteson MT, Halperin JA. The transient pore formed by homologous terminal complement complexes functions as a bidirectional route for the transport of autocrine and paracrine signals across human cell membranes. Mol Med 1996; 2: 755-65.
2. Armati PJ, Pollard JD. Immunology of the Schwann cell. Baillieres Clin Neurol 1996; 5: 47-64.
3. Ashton AC, Rahman MA, Volynski KE, Manser C, Orlova EV, Matsushita H, et al. Tetramerisation of alpha-latrotoxin by divalent cations is responsible for toxin-induced non-vesicular release and contributes to the Ca(2+)-dependent vesicular exocytosis from synaptosomes. Biochimie 2000; 82: 453-68.
4. Auld DS, Robitaille R. Perisynaptic Schwann cells at the neuromuscular junction: nerve- and activity-dependent contributions to synaptic efficacy, plasticity, and reinnervation. Neuroscientist 2003; 9: 144-57.
5. Buchwald B, Weishaupt A, Toyka KV, Dudel J. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 1998; 10: 281-90.
6. Buchwald B, Bufler J, Carpo M, Heidenreich F, Pitz R, Dudel J, et al. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 2001; 56: 67-74.
7. Buchwald B, Ahangari R, Toyka KV. Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and alpha-latrotoxin in the absence of complement at the mouse neuromuscular junction. Neurosci Lett 2002; 334: 25-8.
8. Bullens RWM, O'Hanlon GM, Goodyear CS, Molenaar P, Conner J, Willison HJ, et al. Anti-GQ1b antibodies and evoked acetylcholine release at mouse motor endplates. Muscle Nerve 2000; 23: 1035-43.
9. Bullens RW, O'Hanlon GM, Wagner E, Molenaar PC, Furukawa K, Furukawa K, et al. Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J Neurosci 2002; 22: 6876-84.
10. Castonguay A, Levesque S, Robitaille R. Glial cells as active partners in synaptic functions. Prog Brain Res 2001; 132: 227-40.
11. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 1993; 43: 1911-7.
12. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997; 745: 32-6.
13. Daly CJ, Gordon JF, McGrath JC. The use of fluorescent nuclear dyes for the study of blood vessel structure and function: novel applications of existing techniques. J Vasc Res 1992; 29: 41-8.
14. 2+. EMBO J 1998; 17: 3909-20.
15. Gold R, Archelos JJ, Hartung HP. Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol 1999; 9: 343-60.
16. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, et al. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 1999; 104: 697-708.
17. Hartung HP, Kiefer R, Gold R, Toyka KV. Autoimmunity in the peripheral nervous system. Baillieres Clin Neurol 1996; 5: 1-45.
18. Ho TW, Hsieh ST, Nachamkin I, Willison HJ, Sheikh K, Kiehlbauch J, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997; 48: 717-24.
19. Holt DS, Botto M, Bygrave AE, Hanna SM, Walport MJ, Morgan BP. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 2001; 98: 442-9.
20. Jacobs BC, Bullens RW, O'Hanlon GM, Ang CW, Willison HJ, Plomp JJ. Detection and prevalence of alpha-latrotoxin-like effects of serum from patients with Guillain-Barre syndrome. Muscle Nerve 2002; 25: 549-58.
21. Jones J, Morgan BP. Killing of cells by perforin. Resistance to killing is not due to diminished binding of perforin to the cell membrane. Biochem J 1991; 280: 199-204.
22. Kintner CR, Brockes JP. Monoclonal antibodies to the cells of a regenerating limb. J Embryol Exp Morphol 1985; 89: 37-55.
23. Koski CL, Estep AE, Sawant-Mane S, Shin ML, Highbarger L, Hansch GM. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. J Neurochem 1996; 66: 303-12.
24. Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 1996; 39: 424-31.
25. Lang B, Vincent A. Autoantibodies to ion channels at the neuromuscular junction. Autoimmun Rev 2003; 2: 94-100.
26. Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995; 332: 1467-74.
27. Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002; 110: 1269-74.
28. Marvaud JC, Raffestin S, Popoff MR. Botulism: the agent, mode of action of the botulinum neurotoxins, forms of acquisition, treatment and prevention. [French]. C R Biol 2002; 325: 863-78.
29. McConville J, Vincent A. Diseases of the neuromuscular junction. Curr Opin Pharmacol 2002; 2: 296-301.
30. - channels. Biochem Pharmacol 1999; 57: 491-501.
31. O'Hanlon GM, Plomp JJ, Chakrabarti M, Morrison I, Wagner ER, Goodyear CS, et al. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 2001; 124: 893-906.
32. O'Hanlon GM, Bullens RW, Plomp JJ, Willison HJ. Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective. Neurochem Res 2002; 27: 697-709.
33. O'Hanlon GM, Humphreys PD, Goldman RS, Halstead SK, Bullens RW, Plomp JJ, et al. Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain 2003; 126: 2497-509.
34. Okada M, Itoh MM, Haraguchi M, Okajima T, Inoue M, Oishi H, et al. b-series ganglioside deficiency exhibits no definite changes in the neurogenesis and the sensitivity to Fas-mediated apoptosis but impairs regeneration of the lesioned hypoglossal nerve. J Biol Chem 2002; 277: 1633-6.
35. Orren A, Wallace ME, Hobart MJ, Lachmann PJ. C6 polymorphism and C6 deficiency in site strains of the mutation-prone Peru-Coppock mouse. Complement Inflamm 1989; 6: 295-6.
36. Plomp JJ, Molenaar PC, O'Hanlon GM, Jacobs BC, Veitch J, Daha MR, et al. Miller Fisher anti-GQ1b antibodies: α-latrotoxin-like effects on motor end plates. Ann Neurol 1999; 45: 189-99.
37. Reddy LV, Koirala S, Sugiura Y, Herrera AA, Ko CP. Glial cells maintain synaptic structure and function and promote development of the neuromuscular junction in vivo. Neuron 2003; 40: 563-80.
38. Roberts M, Willison H, Vincent A, Newsom-Davis J. Serum factor in Miller-Fisher variant of Guillain-Barre syndrome and neurotransmitter release. Lancet 1994; 343: 454-5.
39. Rochon D, Rousse I, Robitaille R. Synapse-glia interactions at the mammalian neuromuscular junction. J Neurosci 2001; 21: 3819-29.
40. Sawant-Mane S, Piddlesden SJ, Morgan BP, Holers VM, Koski CL. CD59 homologue regulates complement-dependent cytolysis of rat Schwann cells. J Neuroimmunol 1996; 69: 63-71.
41. Sheikh KA, Griffin JW. Variants of the Guillain Barre syndrome: progress toward fulfilling 'Koch's postulates'. Ann Neurol 2001; 49: 694-6.
42. Spaans F, Vredeveld JW, Morre HH, Jacobs BC, De Baets MH. Dysfunction at the motor end-plate and axon membrane in Guillain-Barre syndrome: a single-fiber EMG study. Muscle Nerve 2003; 27: 426-34.
43. Takamiya K, Yamamoto A, Furukawa K, Yamashiro S, Shin M, Okada M, et al. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Natl Acad Sci USA 1996; 93: 10662-7.
44. Uncini A, Lugaresi A. Fisher syndrome with tetraparesis and antibody to GQ1b: evidence for motor nerve terminal block. Muscle Nerve 1999; 22: 640-4.
45. Vedeler C, Ulvestad E, Bjorge L, Conti G, Williams K, Mork S, et al. The expression of CD59 in normal human nervous tissue. Immunology 1994; 82: 542-7.
46. Vedeler CA, Conti G, Fujioka T, Scarpini E, Rostami A. The expression of CD59 in experimental allergic neuritis. J Neurol Sci 1999; 165: 154-9.
47. Wessig C, Buchwald B, Toyka KV, Martini R. Miller Fisher syndrome: immunofluorescence and immunoelectron microscopic localization of IgG at the mouse neuromuscular junction. Acta Neuropathol (Berl) 2001; 101: 239-44.
48. Willison HJ, O'Hanlon GM. The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol 1999; 100: 3-12.
49. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002; 125: 2591-625.
50. Willison HJ, O'Hanlon GM, Paterson G, Veitch J, Wilson G, Roberts M, et al. A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. J Clin Invest 1996; 97: 1155-64.
51. Willison HJ, O'Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001; 124: 1968-77.
52. Wirguin I, Ifergane G, Almog Y, Lieberman D, Bersudsky M, Herishanu YO. Presynaptic neuromuscular transmission block in Guillain-Barre syndrome associated with anti-GQ1b antibodies. Neuromuscul Disord 2002; 12: 292-3.
53. Wohlleben G, Hartung HP, Gold R. Humoral and cellular immune functions of cytokine-treated Schwann cells. Adv Exp Med Biol 1999; 468: 151-6.
54. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis 2001; 1: 29-37.